The patient population for this study included adults (aged ≥ 18 years) with moderate-to-severe HS. Eligible patients were required to be diagnosed at least 1 year before the baseline visit and have a total abscess and inflammatory nodule (AN) count ≥ 5 at baseline, HS lesions in ≥ 2 distinct anatomical locations, a draining fistula count ≤ 20 at baseline, and inadequate response to oral antibiotics for the treatment of HS. Patients were ineligible to participate if they had exposure to biologic agents blocking IL-12/23, IL-23, or IL-17 within the past 6 months; prior exposure to anti-TNF therapies (except those for the treatment of HS that demonstrated inadequate response); relevant medical conditions (such as hepatitis B, hepatitis C, HIV, or tuberculosis); or if they were pregnant or breastfeeding.
Protocol detail
Moderate-to-Severe Hidradenitis Suppurativa Treatment
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Abscess
Adults
Antibiotics
Biologic agents
Exposure therapies
Fistula
Hepatitis b
Hepatitis c
Il 12
Il 17
Inflammatory
Patients
Tuberculosis
Corresponding Organization : Beth Israel Deaconess Medical Center
Other organizations : Erasmus MC, Centre Méditerranéen de Médecine Moléculaire, Inserm, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, University of California, Davis, University of Fredericton, Probity Medical Research, Dalhousie University, AbbVie (United States), St. Josef-Hospital, Ruhr University Bochum
Top 5 similar protocols
Variable analysis
independent variables
- None explicitly mentioned
- Total abscess and inflammatory nodule (AN) count
- Draining fistula count
- Adults (aged ≥ 18 years) with moderate-to-severe HS
- Diagnosed with HS at least 1 year before the baseline visit
- Total abscess and inflammatory nodule (AN) count ≥ 5 at baseline
- HS lesions in ≥ 2 distinct anatomical locations
- Draining fistula count ≤ 20 at baseline
- Inadequate response to oral antibiotics for the treatment of HS
- No exposure to biologic agents blocking IL-12/23, IL-23, or IL-17 within the past 6 months
- No prior exposure to anti-TNF therapies (except those for the treatment of HS that demonstrated inadequate response)
- No relevant medical conditions (such as hepatitis B, hepatitis C, HIV, or tuberculosis)
- Not pregnant or breastfeeding
- None explicitly mentioned
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!